Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Prostatype Genomics ABFRA:PGO0 -1.96%23 Piotroski F-Score is 4 as of Aug. 09, 2026, which is at its 10-year median of 4.00. GuruFocus rates FRA:PGO0 with a GF Score™ of 23/100. The stock has 5 warning signs investors should review. Among 207 Medical Diagnostics & Research companies, Prostatype Genomics AB ranks worse than 54.59% on this metric.
The zones of discrimination were as such:
Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3
Prostatype Genomics AB has an F-score of 4 indicating the company's financial situation is typical for a stable company.
The historical rank and industry rank for Prostatype Genomics AB's Piotroski F-Score or its related term are showing as below:
FRA:PGO0'
s Piotroski F-Score Range Over the Past 10 Years
Min: 3 Med: 4 Max: 5
Current: 4
During the past 7 years, the highest Piotroski F-Score of Prostatype Genomics AB was 5. The lowest was 3. And the median was 4.
Prostatype Genomics AB (FRA:PGO0) Piotroski F-Score Explanation
The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.
He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.
He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.
What he found was something that exceeded his most optimistic expectations.
Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.
Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).
Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.
Prostatype Genomics AB Piotroski F-Score Related Terms
Prostatype Genomics AB Piotroski F-Score Historical Data
* Premium members only.
The historical data trend for Prostatype Genomics AB's Piotroski F-Score can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:PGO0 vs TMO, DHR, IDXX: Piotroski F-Score Comparison
For the Diagnostics & Research subindustry, Prostatype Genomics AB's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Prostatype Genomics AB Piotroski F-Score vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Prostatype Genomics AB's Piotroski F-Score distribution charts can be found below:
* The bar in red indicates where Prostatype Genomics AB's Piotroski F-Score falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.
Profitability
Question 1. Return on Assets (ROA)
Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.
Score 1 if positive, 0 if negative.
Prostatype Genomics AB's current Net Income (TTM) was -4.09.
==> Negative ==> Score 0.
Question 2. Cash Flow Return on Assets (CFROA)
Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.
Score 1 if positive, 0 if negative.
Prostatype Genomics AB's current Cash Flow from Operations (TTM) was -2.19.
==> Negative ==> Score 0.
Question 3. Change in Return on Assets
Compare this year's return on assets (1) to last year's return on assets.
Prostatype Genomics AB's return on assets of this year was -1.12058098. Prostatype Genomics AB's return on assets of last year was -0.81113636.
==> Last year is higher ==> Score 0.
Question 4. Quality of Earnings (Accrual)
Compare Cash flow return on assets (2) to return on assets (1)
Prostatype Genomics AB's gearing of this year was 0. Prostatype Genomics AB's gearing of last year was 0.
==> This year is lower or equal to last year. ==> Score 1.
Question 6. Change in Working Capital (Liquidity)
Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.
Score 1 if this year's current ratio is higher, 0 if it's lower
Prostatype Genomics AB's current ratio of this year was 0.43738819. Prostatype Genomics AB's current ratio of last year was 1.39106901.
==> Last year's current ratio is higher ==> Score 0.
Question 7. Change in Shares in Issue
Compare the number of shares in issue this year, to the number in issue last year.
Score 0 if there is larger number of shares in issue this year, 1 otherwise.
Prostatype Genomics AB's number of shares in issue this year was 88.795. Prostatype Genomics AB's number of shares in issue last year was 6842.523.
==> There is smaller number of shares in issue this year, or the same. ==> Score 1.
Efficiency
Question 8. Change in Gross Margin
Compare this year's gross margin (Gross Profit divided by sales) to last year's.
Score 1 if this year's gross margin is higher, 0 if it's lower.
Prostatype Genomics AB's gross margin of this year was 1. Prostatype Genomics AB's gross margin of last year was 9.82352941.
==> Last year's gross margin is higher ==> Score 0.
Question 9. Change in asset turnover
Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.
Score 1 if this year's asset turnover ratio is higher, 0 if it's lower
Prostatype Genomics AB's asset turnover of this year was 0.01507262. Prostatype Genomics AB's asset turnover of last year was 0.00386364.
==> This year's asset turnover is higher. ==> Score 1.
Evaluation
Piotroski F-Score
=
Que. 1
+
Que. 2
+
Que. 3
+
Que. 4
+
Que. 5
+
Que. 6
+
Que. 7
+
Que. 8
+
Que. 9
=
0
+
0
+
0
+
1
+
1
+
0
+
1
+
0
+
1
=
4
Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3
Prostatype Genomics AB has an F-score of 4 indicating the company's financial situation is typical for a stable company.
Prostatype Genomics AB (FRA:PGO0) has a Piotroski F-Score of 4 as of Aug. 09, 2026. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on Prostatype Genomics AB and its competitors. This is near median its historical median of 4.00. Over the past decade, Prostatype Genomics AB's Piotroski F-Score has ranged from 3.00 to 5.00. According to the industry distribution chart, Prostatype Genomics AB ranks #113 out of 207 companies in the Medical Diagnostics & Research industry, placing it in the top 54.6%.
Is Prostatype Genomics AB's Piotroski F-Score too high?
Prostatype Genomics AB's current Piotroski F-Score of 4 is near median its 10-year median of 4.00. Over the past 10 years, this metric has ranged from a low of 3.00 to a high of 5.00. The Medical Diagnostics & Research industry median Piotroski F-Score is 5.00. Prostatype Genomics AB's value of 4 is 20% below this industry median. Based on the distribution chart, Prostatype Genomics AB ranks #113 out of 207 companies in the Medical Diagnostics & Research industry, which is below the industry midpoint. Overall, Prostatype Genomics AB has a GF Score™ of 23/100, reflecting its overall financial health beyond just this single metric.
How does Prostatype Genomics AB's Piotroski F-Score compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Prostatype Genomics AB ranks #113 out of 207 companies for Piotroski F-Score. This places Prostatype Genomics AB in the lower half of its industry. The industry median Piotroski F-Score is 5.00. Prostatype Genomics AB's value of 4 is 20% below this benchmark. Historically, Prostatype Genomics AB's own Piotroski F-Score has ranged from 3.00 to 5.00 over the past decade. While the company's 10-year median is 4.00 vs. the industry median of 5.00, Prostatype Genomics AB has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Piotroski F-Score for a Medical Diagnostics & Research company?
The median Piotroski F-Score among Medical Diagnostics & Research companies is 5.00, based on 207 companies in the industry. Companies in the top quartile (top 25%) have a Piotroski F-Score significantly above this median, while those in the bottom quartile fall well below. However, Piotroski F-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Prostatype Genomics AB's current Piotroski F-Score of 4 is 20% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Piotroski F-Score mean?
A high Piotroski F-Score can signal that a stock is expensive relative to its fundamentals. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on Prostatype Genomics AB and its competitors. For the Medical Diagnostics & Research industry, the median Piotroski F-Score is 5.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Prostatype Genomics AB's current Piotroski F-Score is 4, which is near median its own 10-year median of 4.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Prostatype Genomics AB stock overvalued right now?
Prostatype Genomics AB (FRA:PGO0) has a current Piotroski F-Score of 4. The current Piotroski F-Score is 4, which is near median its 10-year median of 4.00 and 20% below the Medical Diagnostics & Research industry median of 5.00. Prostatype Genomics AB's overall GF Score™ is 23/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Piotroski F-Score calculated?
Piotroski F-Score is calculated from a company's financial statements. For Prostatype Genomics AB (FRA:PGO0), the current Piotroski F-Score is 4 as of Aug. 09, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Prostatype Genomics AB manufactures, markets and sells the prognostic gene test Prostatype. By assessing the aggressiveness of prostate cancer, Prostatype helps clinicians and patients to make correct treatment decisions. Over and under treatment of prostate cancer can be minimized, the quality of life for the patient improved and money can be saved for the health care sector.
23GF Score
Get the complete analysis for FRA:PGO0
Piotroski F-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:PGO0 has been successfully added to your 
